At the recent 2025 Advanced Technologies & Treatments for Diabetes congress in Amsterdam, Cognivia presented two new scientific posters demonstrating the applicability and scientific robustness of its data-driven tools, Placebell and Compl-AI, in Type 1 Diabetes (T1D) clinical trials. These results mark a significant step forward in addressing two persistent challenges: data variability and patient drop-out, both of which can compromise statistical power
Experts shared their perspectives from real-world trials on both classical and new approaches to manage the placebo response – and some questions arose throughout the discussion.
Clinical trials measure efficacy of experimental therapies by comparing outcomes in patients receiving therapeutic interventions (treatment response) with patients receiving placebo (placebo response).
In May 2018, Tools4Patient (T4P) presented a webinar entitled “Characterization of Individual Patient Placebo Response: Impact on the Clinical Study Power”.